6,7-二氢-1H-[1,4]二噁英o[2,3:4,5]苯并[d]咪唑-2-硫醇 | 81864-47-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 6,7-二氢-1H-[1,4]二噁英o[2,3:4,5]苯并[d]咪唑-2-硫醇
• 中文别名: 6,7-二氢-1H-[1,4]二氧杂芑并[2',3':4,5]苯并[D]咪唑-2-硫醇
• 英文名称: 1,3,6,7-tetrahydro-2H-[1,4]dioxino[2,3-f]benzimidazole-2-thione
• 英文别名: 1,3,6,7-tetrahydro-[1,4]dioxino[2,3-f]benzimidazole-2-thione
• CAS: 81864-47-3
• 化学式: C₉H₈N₂O₂S
• mdl: MFCD00114695
• 分子量: 208.241
• InChiKey: PMTXBVARJFBMAC-UHFFFAOYSA-N

物化性质

• 熔点：
  300 °C
• 沸点：
  352.3±52.0 °C(Predicted)
• 密度：
  1.55±0.1 g/cm3(Predicted)
• 溶解度：
  19.7 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090

SDS

Name:	6 7-Dihydro-1H-[1 4]dioxino[2 3 :4 5]benzo[d]imidazole-2-thiol 97% Material Safety Data Sheet
Synonym:	5,6-Ethylenedioxy-2-mercaptobenzimidazol
CAS:	81864-47-3

Section 1 - Chemical Product MSDS Name:6 7-Dihydro-1H-[1 4]dioxino[2 3 :4 5]benzo[d]imidazole-2-thiol 97% Material Safety Data Sheet
Synonym:5,6-Ethylenedioxy-2-mercaptobenzimidazol

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
81864-47-3	6,7-Dihydro-1H-[1,4]dioxino[2',3':4,5]	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 81864-47-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: > 300 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H8N2O2S
Molecular Weight: 208

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 81864-47-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
6,7-Dihydro-1H-[1,4]dioxino[2',3':4,5]benzo[d]imidazole-2-thiol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 81864-47-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 81864-47-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 81864-47-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6,7-二氢-1H-[1,4]二噁英o[2,3:4,5]苯并[d]咪唑-2-硫醇 在 sodium hydroxide 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.67h， 生成 9-hydroxy-6-(4-methoxyphenacyl)-2,3,9,10-tetrahydro-8H-[1,4]dioxino[2,3-f][1,3]thiazino[3,2-a]benzimidazolium bromide
  参考文献：
  名称：

  Synthesis and Recylization of 2,3,9,10-Tetrahydro-8H-[1,4]Dioxino[2,3-f]-[1,3]Thiazino[3,2-a]Benzimidazolium Salts

  摘要：

  A series of [1,3]thiazino[3,2-a]benzimidazolium salts modified in the benzene ring by a condensed 1,4-dioxane ring has been prepared. Reaction with epichlorohydrin occurs with recyclization to form derivatives of 3-(2,3-epithiopropyl)benzimidazol-2-one.

  DOI：

  10.1007/s10593-014-1453-z
• 作为产物：
  描述：

  1,2-diamino-4,5-ethylenedioxybenzene dihydrochloride 在 sulfur 作用下， 反应 4.0h， 生成 6,7-二氢-1H-[1,4]二噁英o[2,3:4,5]苯并[d]咪唑-2-硫醇
  参考文献：
  名称：

  Synthesis and Recylization of 2,3,9,10-Tetrahydro-8H-[1,4]Dioxino[2,3-f]-[1,3]Thiazino[3,2-a]Benzimidazolium Salts

  摘要：

  A series of [1,3]thiazino[3,2-a]benzimidazolium salts modified in the benzene ring by a condensed 1,4-dioxane ring has been prepared. Reaction with epichlorohydrin occurs with recyclization to form derivatives of 3-(2,3-epithiopropyl)benzimidazol-2-one.

  DOI：

  10.1007/s10593-014-1453-z

文献信息

• Benzimidazole compound
  申请人：Miyazawa Shuhei

  公开号：US20070010542A1

  公开（公告）日：2007-01-11

  An object of the present invention is to provide a novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases, having an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by where R 1 and R 3 may be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; R 2 represents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy group, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy group, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy group, or (2,2-dimethyl-1,3-dioxan-5-yl)methoxy group; R 4 , R 5 , R 6 and R 7 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and W 1 represents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.

  本发明的目的是提供一种新型化合物，可用作治疗或预防酸相关疾病的药物，具有出色的抑制胃酸分泌作用，保持抑制胃酸分泌作用的出色效果，从而长时间保持胃内pH值高，并具有更高的安全性和适当的理化稳定性。 提供的化合物表示为 其中R 1 和R 3 可以相同也可以不同，每个代表氢原子或C1-C6烷基；R 2 表示(5,5-二甲基-1,3-二氧杂环戊烷-2-基)甲氧基基团，5,7-二氧杂螺[2.5]辛-6-基甲氧基基团，1,5,9-三氧杂螺[5.5]十一烷-3-基甲氧基基团，或(2,2-二甲基-1,3-二氧杂环戊烷-5-基)甲氧基基团； R 4 ，R 5 ，R 6 和R 7 代表氢原子，卤原子，C1-C6烷基，C1-C6卤代烷基，C1-C6烷氧基或C1-C6卤代烷氧基；W 1 表示单键，亚甲基或乙烯基，其盐或这些的溶剂化合物。
• [EN] NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS<br/>[FR] NOUVEAUX DERIVES BENZOIMIDAZOLE CONVENANT COMME AGENTS ANTIPROLIFERATIFS
  申请人：PFIZER PROD INC

  公开号：WO2001040217A1

  公开（公告）日：2001-06-07

  The invention relates to compounds of formula (1) and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R?1, R7, R8, R9, R10, and R11¿ are as defined herein. The invention also relates to methods of treating abnormal cell growth, such as cancer, in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula (1). The invention also relates to methods of preparing the compounds of formula (1).

  本发明涉及公式（1）的化合物及其药学上可接受的盐、前药和溶剂化物，其中R?1、R7、R8、R9、R10和R11¿的定义如本文所述。本发明还涉及通过给哺乳动物施用公式1的化合物来治疗异常细胞生长（如癌症）的方法，以及用含有公式（1）化合物的药物组合物来治疗此类疾病的药物组合物的方法。本发明还涉及制备公式（1）化合物的方法。
• Imidazole derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US04435406A1

  公开（公告）日：1984-03-06

  Tricyclic imidazole derivatives of the formula ##STR1## wherein R.sup.1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R.sup.2 is hydrogen or lower alkyl, R.sup.3 and R.sup.4, independently, are hydrogen or lower alkyl, A is a group of the formula ##STR2## m is the integer 2 or 3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, independently, are hydrogen or lower alkyl, and R.sup.9 is hydrogen and R.sup.10 is hydrogen or lower alkyl or R.sup.9 and R.sup.10 taken together are oxo, provided that at least one of R.sup.3 and R.sup.4 is lower alkyl when A is a group of the formula --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.4 --, and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.

  公式为## STR1 ##的三环咪唑衍生物，其中R.sup.1是2-吡啶基，可以选择性地被低烷基或低烷氧基取代，n是整数0或1，R.sup.2是氢或低烷基，R.sup.3和R.sup.4独立地是氢或低烷基，A是公式## STR2 ##的基团，m是整数2或3，R.sup.5，R.sup.6，R.sup.7和R.sup.8独立地是氢或低烷基，R.sup.9是氢，R.sup.10是氢或低烷基，或者R.sup.9和R.sup.10在一起是氧代基，但当A是公式--CH.dbd.CH--CH.dbd.CH--或--（CH.sub.2）.sub.4--的基团时，R.sup.3和R.sup.4中至少有一个是低烷基，并且它们的药学上可接受的酸盐。公式I的化合物抑制胃酸分泌并预防胃溃疡的形成。
• Pyridyl methyl thio or sulfinyl indeno(5,6-d)imidazoles
  申请人：Hoffmann-La Roche Inc.

  公开号：US04554280A1

  公开（公告）日：1985-11-19

  Tricyclic imidazole derivatives of the formula ##STR1## wherein R.sup.1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R.sup.2 is hydrogen or lower alkyl, R.sup.3 and R.sup.4, independently, are hydrogen or lower alkyl, A is a group of the formula ##STR2## m is the integer 2 or 3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, independently, are hydrogen or lower alkyl, and R.sup.9 is hydrogen and R.sup.10 is hydrogen or lower alkyl or R.sup.9 and R.sup.10 taken together are oxo, provided that at least one of R.sup.3 and R.sup.4 is lower alkyl when A is a group of the formula --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.4 --, and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.

  公式为 ##STR1## 的三环咪唑衍生物，其中R.sup.1是2-吡啶基，可选择地被低烷基或低烷氧基取代，n是整数0或1，R.sup.2是氢或低烷基，R.sup.3和R.sup.4独立地是氢或低烷基，A是公式 ##STR2## 的基团，m是整数2或3，R.sup.5，R.sup.6，R.sup.7和R.sup.8独立地是氢或低烷基，R.sup.9是氢，R.sup.10是氢或低烷基或R.sup.9和R.sup.10一起是氧代，但当A是公式--CH.dbd.CH--CH.dbd.CH--或--（CH.sub.2）.sub.4--的基团时，至少R.sup.3和R.sup.4中的一个是低烷基，它们的药学上可接受的酸盐。公式I的化合物抑制胃酸分泌并预防胃溃疡的形成。
• Tetrahydro-naphth (2.3-d) imidazole derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US04599347A1

  公开（公告）日：1986-07-08

  Tricyclic imidazole derivatives of the formula ##STR1## wherein R.sup.1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 to 1, R.sup.2 is hydrogen or lower alkyl, R.sup.3 and R.sup.4, independently, are hydrogen or lower alkyl, A is a group of the formula ##STR2## m is the integer 2 or 3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, independently, are hydrogen or lower alkyl, and R.sup.9 is hydrogen and R.sup.10 is hydrogen or lower alkyl or R.sup.9 and R.sup.10 taken together are oxo, provided that at least one of R.sup.3 and R.sup.4 is lower alkyl when A is a group of the formula --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.4 --, and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.

  公式为##STR1##的三环咪唑衍生物，其中R.sup.1是2-吡啶基，可选择性地被低烷基或低烷氧基取代，n为整数0至1，R.sup.2为氢或低烷基，R.sup.3和R.sup.4独立地为氢或低烷基，A为公式##STR2##的基团，m为整数2或3，R.sup.5、R.sup.6、R.sup.7和R.sup.8独立地为氢或低烷基，R.sup.9为氢，R.sup.10为氢或低烷基，或R.sup.9和R.sup.10共同为氧代，但当A为--CH.dbd.CH--CH.dbd.CH--或--(CH.sub.2).sub.4--的基团时，R.sup.3和R.sup.4中至少有一个为低烷基。这些公式I的化合物能够抑制胃酸分泌并预防胃溃疡的形成，其药物可接受的酸盐。